It is very uncertain whether siltuximab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
The review found no eligible studies for this question.
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
Levilimab may leads to higher clinical improvement D28b compared with standard care/placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether levilimab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).
It is very uncertain whether levilimab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
Levilimab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
Sarilumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).